Johnson & Johnson beat earnings expectations in the final quarter of 2022 even as a strong dollar and sinking COVID-19 vaccine sales hurt revenue. The health care giant said Tuesday that fourth-quarter earnings slipped 26% to $3.52 billion and revenue declined 4.4% to $23.71 billion. Adjusted earnings totaled $2.35 per share.
J&J tops 4Q earnings forecasts as profit, revenue slip